Report Forecasts An Extraordinary Increase In The Sales of Chantix And Other Prescription Quit Smoking Therapies By 2016
Date: 25 th January 2008
According to a report titled "Pipeline Insight: Substance Dependence - Part I: Nicotine", though the prescription nicotine dependence market is underdeveloped at present, the ever increasing nicotine addiction across the world and the resultant increase in Chantix (varenicline) usage and the launch of newer prescription quit smoking procedures predict that the sales of prescription-based quit smoking medicines and treatment procedures would touch the $4.6 billion mark by 2016. This news report is published at Report Buyer, which is an authentic online business information provider.
The report also predicts that the medicine NIC-002 is likely to achieve $1.3 billion sales by 2016 and it further unveils that the pharmaceutical company Sanofi-Aventis is in possession of two compounds that would soon be released in the market for the treatment of nicotine dependence. Reported to function similar to the Pfizer manufactured quit smoking drug chantix, it is believed that as these products are utilized for short term treatments, they are likely to be advantageous than others.
The authors of the report mention vaccines as the striking treatments of nicotine dependence that are still in the development phase and according to the authors, vaccines are highly usable against nicotine addiction due to the long term treatment offered by them.
Over-all the study report compiles a list of underdeveloped medicines/products to cure nicotine dependence alongside predicting the revenues collected till 2016
from medicine sales. Altogether, the report also tries to throw a glance on the nicotine dependence market, including OTC medicines as well as prescription-based drugs.
Source: Report Buyer |
